Phibro Animal Health (PAHC) Expected to Announce Quarterly Earnings on Wednesday

Phibro Animal Health (NASDAQ:PAHC) is expected to post its Q1 2026 results before the market opens on Wednesday, November 5th. Analysts expect Phibro Animal Health to post earnings of $0.58 per share and revenue of $345.4360 million for the quarter. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS.Interested persons may visit the the company’s upcoming Q1 2026 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 9:00 AM ET.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings results on Wednesday, August 27th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.52 by $0.05. Phibro Animal Health had a net margin of 3.73% and a return on equity of 32.14%. The firm had revenue of $378.70 million during the quarter, compared to analyst estimates of $362.24 million. On average, analysts expect Phibro Animal Health to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Phibro Animal Health Price Performance

Shares of NASDAQ:PAHC opened at $42.06 on Monday. The company has a quick ratio of 1.25, a current ratio of 2.76 and a debt-to-equity ratio of 2.46. The stock has a market capitalization of $1.70 billion, a PE ratio of 35.64, a price-to-earnings-growth ratio of 1.24 and a beta of 0.83. The firm’s 50 day moving average price is $38.89 and its 200-day moving average price is $30.14. Phibro Animal Health has a twelve month low of $16.16 and a twelve month high of $43.65.

Insider Activity

In related news, CEO Jack Bendheim sold 3,520 shares of Phibro Animal Health stock in a transaction that occurred on Thursday, October 30th. The stock was sold at an average price of $41.07, for a total transaction of $144,566.40. Following the sale, the chief executive officer owned 44,440 shares of the company’s stock, valued at approximately $1,825,150.80. This trade represents a 7.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 63,816 shares of company stock worth $2,582,876 in the last three months. Company insiders own 50.13% of the company’s stock.

Institutional Investors Weigh In On Phibro Animal Health

A number of institutional investors have recently added to or reduced their stakes in PAHC. EverSource Wealth Advisors LLC raised its position in shares of Phibro Animal Health by 7,671.4% during the second quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock valued at $69,000 after buying an additional 2,685 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in Phibro Animal Health by 768.2% during the second quarter. Tower Research Capital LLC TRC now owns 4,610 shares of the company’s stock valued at $118,000 after acquiring an additional 4,079 shares in the last quarter. State of Wyoming grew its stake in Phibro Animal Health by 148.8% during the second quarter. State of Wyoming now owns 6,608 shares of the company’s stock valued at $169,000 after acquiring an additional 3,952 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Phibro Animal Health by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock valued at $260,000 after acquiring an additional 546 shares during the last quarter. Finally, Boothbay Fund Management LLC purchased a new stake in Phibro Animal Health in the 2nd quarter worth $322,000. 99.34% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have weighed in on PAHC shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Phibro Animal Health in a research report on Tuesday, October 14th. JPMorgan Chase & Co. raised Phibro Animal Health from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $25.00 to $35.00 in a report on Monday, July 7th. Zacks Research upgraded Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 29th. Morgan Stanley set a $34.00 price target on Phibro Animal Health in a research report on Thursday, August 28th. Finally, Bank of America raised their price objective on Phibro Animal Health from $19.00 to $27.00 and gave the stock an “underperform” rating in a research note on Friday, August 29th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $28.40.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.